** Shares of Grail GRAL.O rise 6.2% to $68.58 premarket

** The cancer test maker says it raised $110 mln via equity sale to Samsung affiliates to support growth and global expansion

** Adds that investment was priced at $70.05 per share

** Notes partnership with Samsung C&T aims to bring Galleri cancer screening test to South Korea and potentially to Japan and Singapore

** Galleri screens for over 50 cancers, including some without routine tests, company said

** Testing initially to be done in North Carolina lab - GRAL

** Test not approved by U.S. FDA and does not detect all cancers, GRAIL adds

** As of last close, stock down ~25% YTD